Dendritic cell targeting in lymph nodes with engineered modular adapters improves HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21

Fabian Weiss,Jonas Kolibius,Patrick C. Freitag,Felix Gantenbein,Anja Kipar,Andreas Plückthun

DOI: https://doi.org/10.1101/2024.04.27.591433

2024-04-28

Abstract:Adenoviral vectors demonstrate encouraging clinical outcomes for B- and T-cell vaccines. With such approaches, multiple payloads can be delivered, beyond the antigen itself. Nevertheless, the human adenoviral vector serotype C5 (HAdV5) exhibits limited transduction efficiency to dendritic cells (DC), therefore necessitating very high viral loads. Targeting antigen-presenting cells (APC) has remained challenging. To solve this problem, we developed a versatile platform that employs modular retargeting adapters to enhance transduction of specific cell types, including challenging host cells. By rational design, we constructed a dual-adapter for DC-SIGN and CD11c and demonstrate successful targeting of HAdV5 to human and murine DCs. Our characterization highlights improved and specific transduction of DCs in draining lymph nodes. Moreover, a tumor vaccination study showcases the advantageous co-expression of T cell stimulatory cytokines (IL-2v or IL-21) locally in lymph nodes alongside a potent tumor antigen. Lymph node-directed gene therapy at significantly reduced vector loads circumvents potential systemic toxicity of stimulating payloads. Our proposed low-dosage DC-targeted vaccine offers an effective solution for patients and also minimizes potential adenovirus-related side-effects. The robust immunogenicity of HC-HAdV5, with its large coding capacity (37 kbp DNA), opens up exciting possibilities for future therapeutic combination strategies.

Biochemistry

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the transduction efficiency of human adenovirus serotype C5 (HAdV5) into dendritic cells (DCs), thereby enhancing the efficacy of HAdV5 - based tumor vaccines. Specifically, the authors developed a modular adapter system that can specifically redirect HAdV5 to specific receptors on the surface of dendritic cells (such as DC - SIGN and CD11c) to enhance transduction into these cells. In addition, the paper also explored methods to further enhance the vaccine efficacy by co - expressing T - cell - stimulating cytokines (such as IL - 2v or IL - 21). This method not only improves the specific transduction of DCs in lymph nodes but also avoids potential systemic toxicity at a significantly reduced viral vector dose, while reducing adenovirus - related side effects. The key points mentioned in the paper include: - **Design of modular adapter**: A dual adapter was constructed through rational design, which can target DC - SIGN and CD11c simultaneously, successfully achieving effective transduction of human and mouse DCs. - **In - vivo characterization**: In - vivo experiments showed that this adapter can effectively redirect HAdV5 to DCs in draining lymph nodes, improving specificity and transduction efficiency. - **Tumor vaccine research**: By locally co - expressing T - cell - stimulating cytokines (IL - 2v or IL - 21) and potent tumor antigens, the potential application of this method in tumor vaccines was demonstrated. - **Advantages of low - dose DC - targeted vaccines**: A low - dose DC - targeted vaccine regimen was proposed, which can not only effectively improve immunogenicity but also reduce potential adenovirus - related side effects, providing new possibilities for future treatment combination strategies.

Dendritic cell targeting in lymph nodes with engineered modular adapters improves HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21

Immunostimulatory activities of dendritic cells loaded with adenovirus vector carrying HBcAg/HBsAg.

Targeted Delivery of Nanovaccine to Dendritic Cells Via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo

Rationally Designed Capsid and Transgene Cassette of AAV6 Vectors for Dendritic Cell‐based Cancer Immunotherapy

Co-transfection Gene Delivery of Dendritic Cells Induced Effective Lymph Node Targeting and Anti-tumor Vaccination

Dendritic Cell Generated from CD34+ Hematopoietic Progenitors Can Be Transfected with Adenovirus Containing Gene of HBsAg and Induce Antigen-Specific Cytotoxic T Cell Responses.

Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.

A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications

CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells

Efficient Generation of Cytotoxic T Lymphocytes Against Cervical Cancer Cells by Adeno-Associated Virus/human Papillomavirus Type 16 E7 Antigen Gene Transduction into Dendritic Cells

Combinational Adenovirus-Mediated Gene Therapy and Dendritic Cell Vaccine in Combating Well-Established Tumors

Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL.

Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors

Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10

Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5

Efficient gene transfer into T lymphocytes by fiber-modified human adenovirus 5

In Vivo Efficacy of Systemic Tumor Targeting of a Viral RNA Vector with Oncolytic Properties Using a Bispecific Adapter Protein.

Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo

HDAd6/35++ - a new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells.